SKP2 and bladder transitional cell carcinoma: ABT-751, an anti-microtubule drug (Table 1), has been reported to inhibit SKP2 transcription by suppression of the AKT serine/threonine kinase–nuclear factor kappa B signaling pathway and to downregulate stable/phospho-SKP2 post-translationally by inhibition of AKT signaling in the urinary bladder urothelial carcinoma cell lines BFTC905 and J82 (Dehghanian et al., 2021) (Table 2).